Lung deposition of inhaled once-daily long-acting muscarinic antagonists <i>via</i> standard jet nebulizer or dry powder inhaler, measured using functional respiratory imaging, in patients with chronic obstructive pulmonary disease.

"Conflict of interest statement: The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: GDC was an employee of Theravance Biopharma US, Inc. when this study was conducted.: KJ is an employee of Theravance Biopharma US, Inc.: JW is an employee of Mylan Pharma UK, Ltd.: JDB is a shareholder and board members of FLUIDDA NV, a company that has commercialized some of the techniques used in this article."

"Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was funded by Theravance Biopharma Ireland Limited (Dublin, Ireland). The authors received medical writing and editorial support, funded by Mylan Inc., a Viatris Company (Canonsburg, Pennsylvania, USA) and Theravance Biopharma US, Inc. (South San Francisco, CA, USA)."